

Title (en)
INTEGRIN ANTAGONISTS

Title (de)
INTEGRINANTAGONISTEN

Title (fr)
ANTAGONISTES DE L'INTEGRINE

Publication
EP 0934305 A4 20010411 (EN)

Application
EP 97938568 A 19970825

Priority

- GB 9703015 A 19970213
- US 9714912 W 19970825
- US 2512396 P 19960829
- US 3357996 P 19961219
- US 4717797 P 19970520

Abstract (en)
[origin: WO9808840A1] This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. The vitronectin receptor antagonist compounds of the present invention are alpha v beta 3 antagonists, alpha v beta 5 antagonists or dual alpha v beta 3/ alpha v beta 5 antagonists useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation and tumor growth.

IPC 1-7
C07D 401/06; A61K 31/415; A61K 31/435

IPC 8 full level
A61K 31/4375 (2006.01); **A61K 31/444** (2006.01); **A61K 31/454** (2006.01); **A61K 31/4545** (2006.01); **A61K 31/4709** (2006.01); **A61K 31/497** (2006.01); **A61K 31/506** (2006.01); **A61P 3/10** (2006.01); **A61P 3/14** (2006.01); **A61P 9/08** (2006.01); **A61P 9/10** (2006.01); **A61P 19/10** (2006.01); **A61P 27/02** (2006.01); **A61P 29/02** (2006.01); **A61P 35/00** (2006.01); **A61P 43/00** (2006.01); **C07D 471/04** (2006.01); **C07D 519/00** (2006.01); **C07K 5/02** (2006.01); **A61K 38/00** (2006.01)

CPC (source: EP)
A61K 31/4375 (2013.01); **A61K 31/444** (2013.01); **A61K 31/454** (2013.01); **A61K 31/4545** (2013.01); **A61K 31/4709** (2013.01); **A61K 31/506** (2013.01); **A61P 3/10** (2017.12); **A61P 3/14** (2017.12); **A61P 9/08** (2017.12); **A61P 9/10** (2017.12); **A61P 19/10** (2017.12); **A61P 27/02** (2017.12); **A61P 29/02** (2017.12); **A61P 35/00** (2017.12); **A61P 43/00** (2017.12); **C07D 471/04** (2013.01); **C07K 5/0202** (2013.01); **A61K 38/00** (2013.01)

Citation (search report)

- [X] WO 9532710 A1 19951207 - MERCK & CO INC [US], et al
- [Y] WO 9517397 A1 19950629 - MERCK & CO INC [US], et al
- [Y] WO 9518111 A1 19950706 - DU PONT MERCK PHARMA [US]
- [Y] WO 9514682 A1 19950601 - DU PONT MERCK PHARMA [US]
- [Y] WO 9514683 A1 19950601 - DU PONT MERCK PHARMA [US]
- [Y] WO 9408577 A1 19940428 - MERCK & CO INC [US], et al
- [PY] WITYAK,J. ET AL.: "Discovery of Potent Isoxazoline Glycoprotein IIb/IIIa Receptor Antagonists", J.MED.CHEM., vol. 40, no. 1, 3 January 1997 (1997-01-03), WASHINGTON, pages 50 - 60, XP002158237
- [PY] XUE,C.B. ET AL.: "Discovery of an Orally Active Series of Isoxazoline Glycoprotein IIb/IIIa Antagonists", J.MED.CHEM., vol. 40, no. 13, 20 June 1997 (1997-06-20), WASHINGTON, pages 2064.2084, XP002158238
- See references of WO 9808840A1

Designated contracting state (EPC)
AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

DOCDB simple family (publication)
WO 9808840 A1 19980305; AU 4086597 A 19980319; AU 724191 B2 20000914; CA 2263999 A1 19980305; EP 0934305 A1 19990811; EP 0934305 A4 20010411; JP 2002511052 A 20020409

DOCDB simple family (application)
US 9714912 W 19970825; AU 4086597 A 19970825; CA 2263999 A 19970825; EP 97938568 A 19970825; JP 51178398 A 19970825